Cytokinetics (CYTK) Operating Leases (2018 - 2024)
Historic Operating Leases for Cytokinetics (CYTK) over the last 9 years, with Q3 2024 value amounting to $114.8 million.
- Cytokinetics' Operating Leases fell 610.72% to $114.8 million in Q3 2024 from the same period last year, while for Sep 2024 it was $114.8 million, marking a year-over-year decrease of 610.72%. This contributed to the annual value of $120.4 million for FY2023, which is 509.71% down from last year.
- Cytokinetics' Operating Leases amounted to $114.8 million in Q3 2024, which was down 610.72% from $116.7 million recorded in Q2 2024.
- Cytokinetics' Operating Leases' 5-year high stood at $126.9 million during Q4 2022, with a 5-year trough of $440000.0 in Q4 2020.
- Over the past 5 years, Cytokinetics' median Operating Leases value was $114.6 million (recorded in 2022), while the average stood at $94.3 million.
- Its Operating Leases has fluctuated over the past 5 years, first tumbled by 8623.66% in 2020, then skyrocketed by 2540659.09% in 2021.
- Quarter analysis of 5 years shows Cytokinetics' Operating Leases stood at $440000.0 in 2020, then surged by 25406.59% to $112.2 million in 2021, then increased by 13.07% to $126.9 million in 2022, then dropped by 5.1% to $120.4 million in 2023, then fell by 4.71% to $114.8 million in 2024.
- Its Operating Leases stands at $114.8 million for Q3 2024, versus $116.7 million for Q2 2024 and $118.6 million for Q1 2024.